<?xml version="1.0" encoding="UTF-8"?>
<p id="par0070">For some platforms, adjuvants may improve their immunogenicity and make it possible to use lower doses, thereby enabling more people to be vaccinated. At least 10 developers have shown plans to develop adjuvanted vaccines against COVID-19, and some of the major vaccine developers, such as GlaxoSmithKline, Seqirus and Dynavax, have promised to offer their adjuvants (AS03, MF59 and CpG 1018, respectively) for vaccines developed by others.</p>
